Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was EGP 545.72 million compared to EGP 381.55 million a year ago. Net income was EGP 76.29 million compared to EGP 70.69 million a year ago. Basic earnings per share from continuing operations was EGP 0.0512 compared to EGP 0.0479 a year ago. Diluted earnings per share from continuing operations was EGP 0.051 compared to EGP 0.0476 a year ago.
For the nine months, sales was EGP 1,388.16 million compared to EGP 1,093.05 million a year ago. Net income was EGP 191.96 million compared to EGP 194.9 million a year ago. Basic earnings per share from continuing operations was EGP 0.1288 compared to EGP 0.1319 a year ago. Diluted earnings per share from continuing operations was EGP 0.1282 compared to EGP 0.1313 a year ago.